Evaluation of Vitamin D isolated or Associated with Teriparatide in Peri-Implant Bone Repair in Tibia of Orchiectomized Rats

SIMPLE SUMMARY: The teriparatide is a drug used to treatment of severe osteoporosis, it is a tissue anabolic agent, this drug increases bone mineral density and increased bone mass. Vitamin D is important to balance of serum calcium and increased calcium absorption from intestine, therefore can be applied to optimize the treatment of osteoporosis. The present study aimed to evaluate the peri-implant bone tissue in rats submitted to orchiectomy, treated with vitamin D alone or associated with teriparatide. Through this in vivo study, it was possible to conclude that the treatment with vitamin D associated with teriparatide in rats with induced osteoporosis increases the volume and improves the bone quality around the implants installed. However, the verification of the behavior of medications that promote an increase in bone density, enabling the establishment of a clinical protocol for the treatment of osteoporosis, is essential, in view of the increase in the population with this bone metabolism disorder in dental offices looking for rehabilitation treatment with dental implants. ABSTRACT: (1) Background: The objective of this study was to evaluate the morphometry of peri-implant bone tissue in orchiectomized rats, treated with vitamin D isolated or associated with teriparatide. (2) Methods: 24 rats were divided into 4 groups: ORQ—orchiectomy, without drug treatment, ORQ+D—orchiectomy, treated with vitamin D, ORQTERI—orchiectomy, treated with teriparatide and ORQTERI+D—orchiectomy, treated with teriparatide + vitamin D. Each animal received an implant in the tibial metaphysis. Euthanasia occurred 60 days after implant surgery. Computed microtomography (micro-CT) was performed to evaluate the parameters of volume and percentage of bone volume (BV, BV/TV), trabecular thickness (Tb.Th), number and separation of trabeculae (Tb.N, Tb.Sp) and percentage of total porosity (Po-tot). Data were subjected to 1-way ANOVA and Tukey post-test, with a significance level of 5%. (3) Results: For the parameters BV, BV/TV, Tb.Th, the ORQTERI+D group showed the highest values in relation to the other groups and for Po-tot, the lowest values were for ORQTERI+D. For Tb.Sp and Tb.N, there was no statistically significant difference when comparing intragroup results (p > 0.05). (4) Conclusions: It was possible to conclude that treatment with vitamin D associated with teriparatide increases bone volume and improves bone quality.